Subskrypcja JoVE jest wymagana do oglądania tego materiału. Zaloguj się lub rozpocznij bezpłatny okres próbny.

Artykuł badawczy

Macrophages in Systemic Lupus Erythematosus: A Bibliometric Analysis of Research Trends and Emerging Frontiers

99 wyświetleń

DOI:

10.3791/72238

11 sierpnia 2026

W tym artykule

Podsumowanie

This study systematically delineates the research landscape and evolving frontiers of the field of systemic lupus erythematosus and macrophages from 2016 to 2025 using bibliometric analysis.

Streszczenie

This study systematically analyzed 1,197 articles on the role of macrophages in systemic lupus erythematosus (SLE) published from 2016 to 2025 using bibliometric methods based on the Web of Science Core Collection. The analysis examined publication trends, collaborative networks, research themes, and the knowledge base to elucidate the current research landscape, core research forces, and frontier evolution in this field. The number of publications peaked at 154 in 2022, while annual citations increased overall from 184 in 2016 to 9,030 in 2025, indicating active and impactful research. China ranked first in publication volume (379 articles), whereas the United States led in total citations (18,838) and international collaboration centrality. Shanghai Jiao Tong University and Karolinska Institutet were the most productive institutions, with 23 articles each. Frontiers in Immunology (impact factor = 5.9; Journal Citation Reports quartile 1) was the most productive journal. Keyword timeline clustering identified 13 major research themes, including key components of innate immunity such as neutrophil extracellular traps, dendritic cells, and Toll-like receptors, as well as adaptive immunity involving T cells, B cells, and plasmacytoid dendritic cells. These themes also included core mechanisms such as macrophage polarization, the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, and apoptotic cell clearance, along with clinical hotspots such as lupus nephritis, macrophage activation syndrome, and rheumatoid arthritis. The evolution of research hotspots reflects a progression from early basic mechanisms of apoptotic cell and immune complex clearance to refined regulation of cytokines, innate immunity, and adaptive immunity, and finally to studies of signaling pathway-targeted therapy, clinical management, and multicenter validation, with “pathway” and “multicenter diagnosis” standing out as current research frontiers.

Wprowadzenie

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of autoantibodies, immune complex deposition, and multi-organ inflammation1,2. Despite substantial advances in diagnostic approaches and therapeutic strategies over recent decades, SLE continues to cause severe damage to the kidneys, hematological system, and central nervous system3,4,5. Existing treatments, including glucocorticoids, immunosuppressants, and biologic agents, generally have limited therapeutic efficacy and are associated with adverse effects to varying degrees6,7,8. Cell engineering strategies, such as chimeric antigen receptor T (CAR-T) cell therapy, have shown the potential to achieve durable drug-free remission in SLE through deep depletion of autoreactive B cells9,10,11. As key members of the innate immune system, macrophages perform crucial functions in immune complex clearance, efferocytosis of apoptotic cells, and cytokine secretion, thereby maintaining immune homeostasis11,12. Accumulating evidence indicates that multiple forms of macrophage dysfunction are implicated in SLE pathogenesis13,14,15. Dysregulated macrophage polarization into proinflammatory M1 versus anti-inflammatory M2 phenotypes has been consistently observed in lupus nephritis, where M1 macrophages promote tissue damage while M2 macrophages contribute to tissue repair as well as fibrotic remodeling16,17. Excessive formation of neutrophil extracellular traps (NETs) and aberrant activation of interferon signaling pathways further amplify macrophage-mediated inflammatory responses18,19,20. Consequently, macrophage dysfunction has emerged not only as a central node in SLE pathogenesis but also as a promising therapeutic target21.

The past decade has witnessed a rapid expansion of publications focusing on the role of macrophages in SLE, spanning diverse research directions, including efferocytosis, NETosis, macrophage polarization, metabolic reprogramming, and targeted modulation of signaling pathways22,23,24,25,26. However, the burgeoning literature also brings challenges, including fragmented research themes, unclear identification of core research forces, and ambiguous mapping of frontier evolution, underscoring the urgent need for a systematic overview of the current research landscape. Bibliometrics employs mathematical and statistical methods to quantitatively analyze the distributional characteristics and evolutionary patterns of knowledge carriers, providing objective data on publication trends, collaborative networks, research hotspots, and frontier dynamics27,28,29,30,31. While bibliometric approaches have been successfully applied to knowledge mapping in SLE immunotherapy, biomarker discovery, and related fields, bibliometric mapping focused specifically on macrophages in SLE remains limited32,33,34. This study retrieves relevant literature from the Web of Science Core Collection database spanning 2016 to 2025 and employs CiteSpace, VOSviewer, and Scimago Graphica to conduct multidimensional visual analyses. By examining publication outputs, country/region and institutional collaborations, author and journal networks, keyword co-occurrence and timeline clustering, as well as citation burst detection, this study aims to systematically elucidate the current research status, core research forces, thematic evolution, and emerging frontiers in the field of macrophages in SLE, thereby providing an objective knowledge map and directional reference for future investigations.

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Protokół

No ethical approval or informed consent was required for this study, as all data were derived from publicly available bibliographic records in the Web of Science Core Collection database. No human participants, animals, or clinical samples were involved in this research.

Data acquisition and search strategy

Data were retrieved from the Web of Science Core Collection (WOSCC) database on a single date (April 27, 2026) to ensure data consistency and reproducibility. The search query employed Boolean operators with the following structure: TS=("Lupus Erythematosus, Systemic" OR "Systemic Lupus Erythematosus" OR "Lupus Erythematosus Disseminatus") AND TS=("macrophage*"). Document types were restricted to articles and review articles. The publication period ranged from January 1, 2016, to December 31, 2025. A total of 1,197 valid papers were retained for subsequent bibliometric analysis.

Analytical tools

An analytical pipeline incorporating multiple software packages was used. CiteSpace (Research Resource Identifier [RRID]: SCR_020932) was used for keyword timeline clustering and citation burst analysis35. VOSviewer (RRID: SCR_016598) was used to construct and visualize coauthorship networks for countries/regions, institutions, and authors, and to generate keyword co-occurrence maps36. Scimago Graphica was used to generate country/region collaboration network visualizations from network files exported from VOSviewer37. Basic statistical calculations and figure preparation were performed using WPS Excel and GraphPad Prism (RRID: SCR_002798). The overall bibliometric workflow is illustrated in Figure 1.

Parameter configuration in CiteSpace and VOSviewer

In CiteSpace, the time slice was set from 2016 to 2025 with 1-year intervals. The g-index (k = 10) was selected as the node selection threshold. The Pathfinder pruning algorithm was applied twice: first to simplify each individual time slice network, and again after merging all slices to reduce visual complexity. In VOSviewer, the LinLog/modularity algorithm was chosen for network layout optimization. Node sizes were weighted by document counts or citation frequencies, depending on the specific analysis. For country/region collaboration mapping using Scimago Graphica, node diameters reflected publication volumes, and link thickness represented collaboration intensities between countries.

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Wyniki

Roczna liczba publikacji

W latach 2016–2025 opublikowano łącznie 1197 artykułów na temat makrofagów w SLE. Roczna liczba publikacji ulegała wahaniom, zaczynając od 112 w 2016 roku, osiągając szczyt na poziomie 154 w 2022 roku, a następnie nieznacznie spadając do 133 w 2025 roku. W tym samym okresie całkowita roczna liczba cytowań wzrosła z 184 do 9030, z niewielkimi wahaniami, co wskazuje na stopniowy wzrost wpływu akademickiego w tej dziedzinie (Rysunek 2...

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Dyskusja

This bibliometric study systematically delineates the research landscape of macrophages in SLE over the past decade (2016–2025). By analyzing 1,197 publications from the Web of Science Core Collection, we identified global publication trends, collaborative networks, core research forces, thematic evolution, and knowledge base dynamics, thereby providing an objective roadmap for future investigations in this rapidly evolving field.

Over the 10-year study period, annual publications on mac...

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Oświadczenia

The authors have no conflicts of interest to declare. No AI-assisted tools were used in the preparation of this manuscript, including data analysis, figure generation, or writing.

Podziękowania

This work was supported by the Excellence & Innovation Initiative of China-Japan Friendship Hospital (Grant No. ZRZC2025-KCC02), the National High Level Hospital Clinical Research Funding (Grant No. 2025-NHLHCRF-JBGS-B-WZ-15), the National Natural Science Foundation of China (Grant No. 82400846), the Major New Drug Innovation Project of the Ministry of Science and Technology of China (Grant No. 2017ZX09301001), and the Russian National Science Foundation Foreign Top Scientists Program (Grant No. 257431017).

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Materiały

Lista materiałów użytych w tym artykule
NazwaFirmaNumer katalogowyKomentarze
CiteSpace (version 6.4.R1)Drexel University, Philadelphia, PA, USAN/AKeyword timeline clustering and citation burst analysis; RRID: SCR_020932; URL: https://citespace.podia.com
GraphPad Prism (version 10.1)Dotmatics, Boston, MA, USAN/AFigure preparation and data visualization; RRID: SCR_002798; URL: https://www.graphpad.com
Scimago Graphica (version 1.0.25)Scimago Lab, Madrid, SpainN/ACountry/region collaboration network visualization; RRID: not available; URL: https://www.graphica.app
VOSviewer (version 1.6.19)Centre for Science and Technology Studies, Leiden University, Leiden, NetherlandsN/ACoauthorship network construction and keyword co-occurrence mapping; RRID: SCR_016598; URL: https://www.vosviewer.com
Web of Science Core CollectionClarivate Analytics, Philadelphia, PA, USAN/ALiterature retrieval and data source; URL: https://clarivate.com/webofscience
WPS Excel (2023)Kingsoft, Zhuhai, ChinaN/ABasic statistical calculations and bar, line, and pie charts; RRID: not available; URL: https://www.wps.com

Bibliografia

  1. Tanaka Y. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2022;36(4):101814.
  2. Cascarano G, et al. Systemic lupus erythematosus: one year in review 2026. Clin Exp Rheumatol. 2026;44(3):427-37.
  3. Mejia-Vilet JM, Turner-Stokes T, Houssiau F, Rovin BH. Kidney involvement in systemic lupus erythematosus: from the patient assessment to a tailored treatment. Best Pract Res Clin Rheumatol. 2023;37(4):101925.
  4. Zheng Z, et al. Immune thrombocytopenia in patients with systemic lupus erythematosus. Clin Rheumatol. 2025;44(1):97-104.
  5. Justiz-Vaillant AA, et al. Neuropsychiatric systemic lupus erythematosus: molecules involved in its immunopathogenesis, clinical features, and treatment. Molecules. 2024;29(4):747.
  6. Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29.
  7. Su X, et al. Systemic lupus erythematosus: pathogenesis and targeted therapy. Mol Biomed. 2024;5(1):54.
  8. Morand EF, Fernandez-Ruiz R, Blazer A, Niewold TB. Advances in the management of systemic lupus erythematosus. BMJ. 2023;383:e073980.
  9. Mackensen A, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124-32.
  10. Wang Q, et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N Engl J Med. 2025;393(15):1542-4.
  11. Wang W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024;83(10):1304-14.
  12. Bao Y, Wang G, Li H. Approaches for studying human macrophages. Trends Immunol. 2024;45(4):237-47.
  13. Bernier ED, Bartnicki E, Khanna KM. Macrophages: sentinels, warriors, and healers. Hum Mol Genet. 2025;34(R1):R110-20.
  14. Zhang L, Sheng J, Liu T. Macrophages in lupus nephritis: insights into its pathogenesis and emerging treatments. Front Biosci (Landmark Ed). 2025;30(10):39365.
  15. Yang S, Zhao M, Jia S. Macrophage: key player in the pathogenesis of autoimmune diseases. Front Immunol. 2023;14:1080310.
  16. Chavanisakun C, Keawvichit R, Benjakul N. M1 and M2 macrophage polarization correlates with activity and chronicity indices in lupus nephritis. Life (Basel). 2025;15(1):55.
  17. Zhao L, et al. Regulation of macrophage polarization by targeted metabolic reprogramming for the treatment of lupus nephritis. Mol Med. 2024;30(1):96.
  18. Fresneda Alarcon M, McLaren Z, Wright HL. Neutrophils in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus: same foe different M.O. Front Immunol. 2021;12:649693.
  19. Postal M, et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. 2020;67:87-94.
  20. Lood C, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016;22(2):146-53.
  21. Cutolo M, et al. Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases. Nat Rev Rheumatol. 2025;21(9):546-65.
  22. Wu R, et al. Polydopamine-encapsulated probiotics restore gut homeostasis and reinstate macrophage efferocytosis in systemic lupus erythematosus. Adv Sci (Weinh). 2026;13(24):e22637.
  23. Suvandjieva V, et al. Modelling the impact of NETosis during the initial stage of systemic lupus erythematosus. Bull Math Biol. 2024;86(6):66.
  24. Zhao CL, et al. Long non-coding RNA H19 contributes to M1 macrophage polarization mediated inflammation via miR-145-5p-PAI-1 axis in systemic lupus erythematosus. Autoimmunity. 2026;59(1):2649582.
  25. Su H, et al. Glucose metabolic reprogramming in systemic lupus erythematosus and lupus nephritis: theoretical foundations and therapeutic implications. Front Immunol. 2026;17:1799232.
  26. Lv Q, et al. ANGPTL3 in podocytes contributes to the pathogenesis of lupus nephritis by activating MSR1 in macrophages. Kidney Dis (Basel). 2026;12(1):288-301.
  27. Chen G, Yan Z, Wang Y, Tao Q. Rheumatoid arthritis and fibromyalgia syndrome: a bibliometric and bioinformatics perspective on comorbidity research. J Multidiscip Healthc. 2025;18:6811-27.
  28. Wang Y, et al. Research trends and hotspots in JAK inhibitors for ulcerative colitis: a bibliometric analysis from 2015 to 2024. J Multidiscip Healthc. 2025;18:6755-71.
  29. Ma L, Yao T, Jin D, Yan Z. Mapping the knowledge landscape of muscle disorders in rheumatoid arthritis: a bibliometric and bioinformatics study. J Vis Exp. 2026;(230):e70373.
  30. Jia MY, Bai XX. Mapping the knowledge landscape of atopic dermatitis and allergic rhinitis comorbidity: a bibliometrics study. J Vis Exp. 2026;(230):e70363.
  31. Zhao Y, Chen GY, Fang M. Research trends of rheumatoid arthritis and depression from 2019 to 2023: a bibliometric analysis. J Multidiscip Healthc. 2024;17:4465-74.
  32. Fu D, Cao Y, Ma T, Wu H. A bibliometric analysis on immunotherapy treatments for systemic lupus erythematosus: analysis of published evidence from 2014 to 2024. Clin Rheumatol. 2026;45(2):831-44.
  33. Yan YL, et al. Research trends of the aetiology of systemic lupus erythematosus in the past 10 years: a bibliometric analysis (2014-2023). Clin Exp Rheumatol. 2025;43(9):1650-60.
  34. Yu H, et al. Mapping theme evolution and identifying hotspots in biomarkers of systemic lupus erythematosus based on global research. Biomark Med. 2024;18(7):321-32.
  35. Synnestvedt MB, Chen C, Holmes JH. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc. 2005;2005:724-8.
  36. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523-38.
  37. Wang YF, et al. Global trends and hotspots of artificial intelligence in pain management: a bibliometric analysis. Digit Health. 2026;12:20552076261460708.
  38. Anders HJ, et al. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7.
  39. Jing C, et al. Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis. Proc Natl Acad Sci U S A. 2020;117(26):15160-71.
  40. Tsokos GC, et al. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716-30.
  41. Mohammadi S, Saghaeian-Jazi M, Sedighi S, Memarian A. Immunomodulation in systemic lupus erythematosus: induction of M2 population in monocyte-derived macrophages by pioglitazone. Lupus. 2017;26(12):1318-27.
  42. Funes SC, et al. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154(2):186-95.
  43. Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2019;58(1):5-17.
  44. da Cruz HLA, et al. Differential expression of the inflammasome complex genes in systemic lupus erythematosus. Immunogenetics. 2020;72(4):217-24.
  45. Caricchio R, Gallucci S. Systemic lupus erythematosus and cytokine storm. Adv Exp Med Biol. 2024;1448:355-64.
  46. Ahamada MM, Jia Y, Wu X. Macrophage polarization and plasticity in systemic lupus erythematosus. Front Immunol. 2021;12:734008.
  47. Sadeghi M, et al. Neutrophil extracellular trap: a key player in the pathogenesis of autoimmune diseases. Int Immunopharmacol. 2023;116:109843.
  48. Wang X, et al. Recent advances of type I interferon on the regulation of immune cells and the treatment of systemic lupus erythematosus. J Inflamm Res. 2025;18:4533-49.
  49. Hanata N, Kaplan MJ. The role of neutrophil extracellular traps in inflammatory rheumatic diseases. Curr Opin Rheumatol. 2025;37(1):64-71.
  50. Lee S, et al. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature. 2021;597(7876):415-9.
  51. Kraaij T, et al. A novel method for high-throughput detection and quantification of neutrophil extracellular traps reveals ROS-independent NET release with immune complexes. Autoimmun Rev. 2016;15(6):577-84.
  52. Li Q, Liu H, Yin G, Xie Q. Efferocytosis: current status and future prospects in the treatment of autoimmune diseases. Heliyon. 2024;10(7):e28399.
  53. Dehdashtian E, Caricchio R. From innate immunity to autoimmunity: neutrophils in systemic lupus erythematosus pathogenesis. Lupus. 2025;34(10):989-1002.
  54. Maria NI, Davidson A. Renal macrophages and dendritic cells in SLE nephritis. Curr Rheumatol Rep. 2017;19(12):81.
  55. Ma C, Xia Y, Yang Q, Zhao Y. The contribution of macrophages to systemic lupus erythematosus. Clin Immunol. 2019;207:1-9.
  56. Kahlenberg JM, Kaplan MJ. The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis? Curr Opin Rheumatol. 2014;26(5):475-81.
  57. Khorasani S et al. Amelioration of regulatory T cells by Lactobacillus delbrueckii and Lactobacillus rhamnosus in pristane-induced lupus mice model. J Cell Physiol. 2019;234(6):9778-9786.
  58. Xu H, Yuan K, Chen G. Single-cell transcriptomics reveals CCL3+ classical monocyte subset linked to autoimmune pathogenesis. J Inflamm Res. 2025;18:16273-91.
  59. Wei S, et al. Integrative analysis of single-cell and bulk transcriptome data reveal the significant role of macrophages in lupus nephritis. Arthritis Res Ther. 2024;26(1):84.
  60. Nehar-Belaid D et al. Mapping systemic lupus erythematosus heterogeneity at the single-cell level. Nat Immunol. 2020;21(9):1094-1106.
  61. Liu SY, et al. Hydroxychloroquine enhances efferocytosis and modulates inflammation via MerTK/Gas6 signaling in a pristane-induced lupus mouse model. Front Immunol. 2025;16:1524315.
  62. Xing Y, et al. Single-cell spatial transcriptomics reveals pathogenic mechanism of renal fibrosis in imiquimod-induced lupus nephritis in mice. Biochem Biophys Rep. 2025;43:102087.
  63. Zhao J, et al. Cxcl9high macrophages recruit circulating Cxcr3+ plasmablasts into kidneys to promote pathogenesis of lupus nephritis mice. Commun Biol. 2025;8(1):1446.
  64. Zhou H, et al. Machine learning combined multi-omics analysis to explore key oxidative stress features in systemic lupus erythematosus. Front Immunol. 2025;16:1567466.
  65. Wang K, Li X, Tang Y, Zhao L. Exploring key genes of glutathione metabolism in systemic lupus erythematosus based on Mendelian randomisation, single-cell RNA sequencing and multiple machine learning approaches. IET Syst Biol. 2025;19(1):e70021.
  66. Lee M, et al. Inhibition of salt-inducible kinases resolves autoimmune arthritis by promoting macrophage efferocytosis. Signal Transduct Target Ther. 2025;10(1):293.
  67. Hoover PJ, et al. A human-mouse atlas of intrarenal myeloid cells identifies conserved disease-associated macrophages in lupus nephritis. J Exp Med. 2025;222(11):e20241873.
  68. Zhu H, et al. The expression and clinical significance of different forms of Mer receptor tyrosine kinase in systemic lupus erythematosus. J Immunol Res. 2014;2014:431896.
  69. Yin Y, et al. Amino acid metabolism modulates macrophage polarization: implications for autoimmune-related diseases. Front Immunol. 2026;17:1736082.

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Przedruki i uprawnienia

Tagi

Polaryzacja makrofagówodporność wrodzonaodporność nabytainflamasom NLRP3usuwanie komórek apoptotycznychtoczeń nerkowyreceptory Toll-podobnezespół aktywacji makrofagów